<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969107</url>
  </required_header>
  <id_info>
    <org_study_id>TMEabdVSta</org_study_id>
    <nct_id>NCT04969107</nct_id>
  </id_info>
  <brief_title>Abdominal or Transanal TME for Rectal Cancer Therapy</brief_title>
  <official_title>Abdominal or Transanal TME in Therapy of Rectal Cancer: A Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed whether transanal TME in patients with rectal cancer is superior to open,&#xD;
      laparoscopic, and robotic TME (abdominal TME (abTME)) regarding oncological outcome,&#xD;
      postoperative morbidity and 90-day mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rectal cancer accounts for 3.8% of all new cancer diagnosis and for 3.4% of all&#xD;
      cancer-related deaths in the world in 2020. Regarding treatment of rectal cancer, it is&#xD;
      essential to perform surgery along the anatomical and embryological planes. This technique&#xD;
      called total mesorectal excision (TME) reduces the local recurrence rate and improves the&#xD;
      survival. Since the early 2000, TME has changed from open to laparoscopic approach due to&#xD;
      better results in short-term outcome. Nevertheless, oncological benefits are modest. In 2009&#xD;
      the first ever transanal TME (taTME) war performed. This novel technique combines abdominal&#xD;
      with transanal dissection. Because the distal part of the rectum is approached from below, a&#xD;
      better visualization of the mesorectal plane resulting in higher rate of free CRM and of&#xD;
      complete TME specimen grade (Quirke Score) can be accomplished. However, taTME remains a hot&#xD;
      topic in the current scientific literature. In Norway and the Netherlands a higher rate of&#xD;
      anastomotic leakage as well as a higher rate of local recurrence (9.5%) with multifocal&#xD;
      growth pattern were described.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>time from surgery to end of follow-up or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cancer-specific survival</measure>
    <time_frame>60 months</time_frame>
    <description>time from surgery to end of follow-up or death due to rectal cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disease-specific survival</measure>
    <time_frame>60 months</time_frame>
    <description>time from surgery to end of follow-up or death due to or recurrence of rectal cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>positive resection margin</measure>
    <time_frame>30 days</time_frame>
    <description>tumor extending to the resection margin in pathological examination (R0, R1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quirke Score</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of mesorectal excision in pathological examination (Good, modest, bad)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circular resection margin (CRM)</measure>
    <time_frame>30 days</time_frame>
    <description>size of circular resection margin (mm) in pathological examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of lymph nodes</measure>
    <time_frame>30 days</time_frame>
    <description>number of lymph nodes in pathological examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with postoperative complications (bleeding, anastomotic leakage, ileus, sacral infect, fistula, other surgical complications). The complications will be classified according the Clavien-Dindo-Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative 90-day mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Number of patients who die in the first 90 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>60 months</time_frame>
    <description>local recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>60 months</time_frame>
    <description>local or systemic recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Survival</condition>
  <condition>Postoperative Morbidity</condition>
  <condition>Mortality</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>transanal TME (taTME)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with rectal cancer receiving transanal TME</description>
  </arm_group>
  <arm_group>
    <arm_group_label>abdominal TME (abTME)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with rectal cancer receiving open, laparoscopic or robotic TME</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>taTME</intervention_name>
    <description>Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.</description>
    <arm_group_label>transanal TME (taTME)</arm_group_label>
    <other_name>transanal total mesorectal excision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>abdTME</intervention_name>
    <description>Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.</description>
    <arm_group_label>abdominal TME (abTME)</arm_group_label>
    <other_name>abdominal total mesorectal excision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients receiving elective total mesorectal excision&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosis other than rectal cancer&#xD;
&#xD;
          -  partial mesorectal excision&#xD;
&#xD;
          -  discontinuity resection (no anastomosis)&#xD;
&#xD;
          -  incomplete Staging&#xD;
&#xD;
          -  metastatic cancer&#xD;
&#xD;
          -  lack of follow-up&#xD;
&#xD;
          -  decline of a retrospective data Analysis&#xD;
&#xD;
          -  age under 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Marti, Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Leitender Arzt, Chirurige KSSG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of surgery, Cantonal hospital of St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>Saint Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>Lukas Marti</investigator_full_name>
    <investigator_title>Dr. med. Lukas Marti, Leitender Arzt Chirurgie</investigator_title>
  </responsible_party>
  <keyword>TME</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>transanal</keyword>
  <keyword>local recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

